Characteristics of the batokine exchange dynamics in patients with coronary heart dis-ease and obesity on the background of therapy

Abstract

The article analyzes the dynamics of batokine levels: vascular endothelial growth factor A (VEGFa) and fibroblast growth factor (FGF-21) in patients with comorbidity of coronary heart disease (CHD) and obesity against the background of therapy. The aim of the research was to study the dynamics of FGF-21 and VEGFa levels in individuals with comorbidity of CHD and obesity against the background of therapy. 130 people aged from 25 to 85 were exa­mined: Group I included 70 patients with CHD in combination with obesity, Group II – 35 patients with isolated CHD, Тhe control group (Group III) included 25 healthy people without any cardiovascular diseases. The Group I included 26 (37.1%) patients with the Ist degree of obesity, 24 (34.3%) patients with the IInd degree of obesity, and 20 (28.6%) with the IIIrd degree of obesity. During the study, standard ethical requirements for similar studies were met, which was confirmed by the conclusion of the Bioethics Committee of the Kharkiv National Medical University. In the research FGF21 and VEGFA levels were established. These indicators were restored after treatment. The dynamics of the decrease in the levels of FGF21 (by 23.6 pg/ml) and VEGFA (by 11.1 pg/ml) after treatment was better in patients of the I group (p<0.001). In the II group, there was a decrease in the levels of FGF21 (by 10.5 pg/ml; p=0.001) and VEGFA (by 2.2 pg/ml; p=0.154). According to obesity levels, the dynamics of FGF21 recovery was better for grades I (by 29.1 pg/ml; p=0.004) and II (by 55.7 pg/ml; p<0.001). A significant (p<0.001) increase in the level of FGF21 after treatment by 22.5 pg/ml was observed in degree III obesity. Probable (p<0.001) better dynamics of recovery of VEGFA level was observed in obesity of III degree (decrease by 13.8 pg/ml), compared to II and I degrees (decrease by 9.8 pg/ml and 10.2 pg/ml). Treatment of patients with CHD on the background of obesity determined its effectiveness in restoring the levels of FGF21 and VEGFA. Keywords: coronary heart disease and obesity comorbidity, isolated coronary heart disease, batokines, FGF21, VEGFA.